- Zacks•2 days ago
Shire's (SHPG) fourth-quarter results were encouraging with the company beating both top- and bottom-line estimates.
- Investopedia•2 days ago
Baxalta’s contributions helped Shire beat Wall Street expectations for earnings and revenues.
- Investor's Business Daily•3 days ago
Despite drugmaker Shire's lagging sales in oncology and neuroscience, the company topped Wall Street's Q4 views and delivered in-line 2017 guidance — prompting the stock to pop.
SHPG : Summary for Shire plc - American Depositary - Yahoo Finance
Shire plc (SHPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||160.15 x 100|
|Ask||183.98 x 200|
|Day's Range||179.02 - 181.81|
|52 Week Range||161.09 - 209.22|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||276.88|
|Dividend & Yield||0.80 (0.44%)|
|1y Target Est||N/A|